Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

4306studies shown

Showing 817-828 of 4,306

Recruitment unclearEUCTR 2019-003343-29

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Bulgaria, Croatia, Czechia, ...
Sponsor: ACADIA Pharmaceuticals Inc.
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2019-002259-40

A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Romania

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Romania
Sponsor: Sunovion Pharmaceuticals Inc.
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2009-011594-33

A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Germany
Sponsor: LWL University Hospital Bochum, Ruhr-University Bochum
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2008-001015-38

A randomized, placebo-controlled study of the central cannabinoid (CB1) receptor antagonist rimonabant as adjunctive therapy to improve cognition in schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Germany
Sponsor: LWL University Hospital Bochum, Ruhr-University Bochum
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2021-001278-44

Comparative analysis of the effectiveness of clozapine in resistant schizophrenia and schizoafective disorder.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Spain

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Spain
Sponsor: Fundación Hospital Provincial de Castellón
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2010-018416-33

Effets du Fénofibrate durant la première année de schizophrénie (effects of Fenofibrate® in first year of schizophrenia)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: France
Sponsor: Centre Hospitalier Régional et Universitaire de Lille
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2005-003156-35

Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Schizophrenia.

Schizophrenia, AddictionDrug

Countries: Germany
Sponsor: Department of Psychiatry and Psychotherapy (Cologne)
Condition: Schizophrenia, Addiction

View study

Recruitment unclearEUCTR 2007-002245-20

Evaluation of potential central glucoregulatory compounds to treat/ameliorate the symptoms of schizophrenia: a proof-of-concept study in healthy volunteers

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBiological

Countries: Germany
Sponsor: Zentralinstitut für Seelische Gesundheit Mannheim
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2006-002342-11

Multicenter study of neurotransmitters and neuropeptides in schizophrenia: A multidisciplinary study of biological, pharmacokinetic, receptor occupancy and clinical relationships in patients suffer...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Germany
Sponsor: Klinikum Fulda gAG
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2008-005019-16

Randomized Olanzapine Clozapine Key study on Schizophrenia and Addiction in the Netherlands (ROCKSAN)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Netherlands

Why is this study shown?

This study is directly about Schizophrenia.

Schizophrenia, AddictionDrug

Countries: Netherlands
Sponsor: AMC- academisch psychiatrisch centrum
Condition: Schizophrenia, Addiction

View study

Recruitment unclearEUCTR 2013-002713-35

Randomized, controlled trial of the effectiveness of add-on tolcapone to usual antipsychotic therapy on cognitive and negative symptoms of patients with schizophrenia genotyped for COMT polymorphisms

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Greece

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Greece
Sponsor: MediPsych SA
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2007-004857-27

Ventral striatal function in patients with schizophrenia before and under medication with atypical antipsychotics: a comparison of sertindole and risperidone

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Germany
Sponsor: Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich
Condition: Schizophrenia

View study

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.